The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Therapeutic lymphangiogenesis with human recombinant VEGF‐C
Abstract
Chronic regional impairments of the lymphatic circulation often lead to striking architectural abnormalities in the lymphedematous tissues. Lymphedema is a common, disabling disease that currently lacks a cure. Vascular endothelial growth factors C and D mediate lymphangiogenesis through the VEGFR‐3 receptor on lymphatic endothelia. The purpose of this study was to investigate the therapeutic potential for lymphangiogenesis with VEGF‐C. We developed a rabbit ear model to simulate human chronic postsurgical lymphatic insufficiency. Successful, sustained surgical ablation of the ear lymphatics was confirmed by water displacement volumetry. After complete healing, the experimental animals (n=8) received a single, s.c. 100 μg dose of VEGF‐C in the operated ear; controls (n=8) received normal saline. Radionuclide lymphoscintigraphy was performed to quantitate lymphatic function. Immunohistochemistry (IHC) was performed 7–8 days following treatment. After VEGF‐C, there was a quantifiable amelioration of lymphatic function. IHC confirmed a significant increase in lymphatic vascularity, along with reversal of the intense tissue hypercellularity of untreated lymphedema. This study confirms the capacity of a single dose of VEGF‐C to induce therapeutic lymphangiogenesis in acquired lymphedema. In addition to improving lymphatic function and vascularity, VEGF‐C can apparently reverse the abnormalities in tissue architecture that accompany chronic lymphatic insufficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
Skobe, M., Hawighorst, T., Jackson, D. G., Prevo, R., Janes, L., Velasco, P., Riccardi, L., Alitalo, K., Claffey, K., & Detmar, M. (2001) · Nature Medicine · doi:10.1038/84643 · Cited by 1,733
Self-citationJoukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lahtinen, I., Kukk, E., Saksela, O., Kalkkinen, N., & Alitalo, K. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00359.x · Cited by 1,672
Self-citationKaipainen, A., Korhonen, J., Mustonen, T., van Hinsbergh, V. W., Fang, G. H., Dumont, D., Breitman, M., & Alitalo, K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3566 · Cited by 1,423
Self-citationHyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice
Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X., Lakso, M., Rauvala, H., Swartz, M., Fukumura, D., Jain, R. K., & Alitalo, K. (1997) · Science · doi:10.1126/science.276.5317.1423 · Cited by 1,283
Self-citationBaumgartner, I., Pieczek, A., Manor, O., Blair, R., Kearney, M., Walsh, K., & Isner, J. M. (1998) · Circulation · doi:10.1161/01.cir.97.12.1114 · Cited by 1,098
Clinical applications of angiogenic growth factors and their inhibitors
Ferrara, N., & Alitalo, K. (1999) · Nature Medicine · doi:10.1038/70928 · Cited by 1,004 · cited 1×
“Therapeutic lymphangiogenesis may hold significant promise for lymphatic vascular insufficiency (34), in analogy to the proposed treatment strategies for circulatory insufficiency of the myocardium and other major vascular beds (35, 36).”
BackgroundSelf-citationCardiovascular Failure in Mouse Embryos Deficient in VEGF Receptor-3
Dumont, D. J., Jussila, L., Taipale, J., Lymboussaki, A., Mustonen, T., Pajusola, K., Breitman, M., & Alitalo, K. (1998) · Science · doi:10.1126/science.282.5390.946 · Cited by 874
Self-citationRegulation of angiogenesis via vascular endothelial growth factor receptors.
Veikkola, T., Karkkainen, M. J., Claesson, L., & Alitalo, K. K. (2000) · PubMed · Cited by 864
Self-citationGale, N. W., & Yancopoulos, G. D. (1999) · Genes & Development · doi:10.1101/gad.13.9.1055 · Cited by 784
Proteolytic processing regulates receptor specificity and activity of VEGF-C
Joukov, V., Sorsa, T., Kumar, V., Jeltsch, M., Claesson-Welsh, L., Cao, Y., Saksela, O., Kalkkinen, N., & Alitalo, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3898 · Cited by 773
Self-citation
Cited by
Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration
Rafii, S., & Lyden, D. (2003) · Nature Medicine · doi:10.1038/nm0603-702 · Cited by 1,577
The lymphatic vasculature in disease
Alitalo, K. (2011) · Nature Medicine · doi:10.1038/nm.2545 · Cited by 962
Self-citationTumour vascularization: sprouting angiogenesis and beyond
Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583
Cardiac lymphatics are heterogeneous in origin and respond to injury
Klotz, L., Norman, S., Vieira, J. M., Masters, M., Rohling, M., Dubé, K. N., Bollini, S., Matsuzaki, F., Carr, C. A., & Riley, P. R. (2015) · Nature · doi:10.1038/nature14483 · Cited by 506
Lymphatic vasculature development
Oliver, G. (2004) · Nature Reviews Immunology · doi:10.1038/nri1258 · Cited by 461
Gene transfer as a tool to induce therapeutic vascular growth
Ylä-Herttuala, S., & Alitalo, K. (2003) · Nature Medicine · doi:10.1038/nm0603-694 · Cited by 404
Self-citationSaharinen, P., Tammela, T., Karkkainen, M. J., & Alitalo, K. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.05.003 · Cited by 391
Self-citationTammela, T., Saaristo, A., Holopainen, T., Lyytikkä, J., Kotronen, A., Pitkonen, M., Abo-Ramadan, U., Ylä-Herttuala, S., Petrova, T. V., & Alitalo, K. (2007) · Nature Medicine · doi:10.1038/nm1689 · Cited by 364
Self-citationNew developments in clinical aspects of lymphatic disease
Mortimer, P. S., & Rockson, S. G. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71608 · Cited by 357
Self-citationFocus on lymphangiogenesis in tumor metastasis
Achen, M. G., McColl, B. K., & Stacker, S. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.017 · Cited by 351
Lymphatic Vessel Network Structure and Physiology
Breslin, J. W., Yang, Y., Scallan, J. P., Sweat, R. S., Adderley, S. P., & Murfee, W. L. (2018) · Comprehensive Physiology · doi:10.1002/cphy.c180015 · Cited by 341
Lim, H. Y., Thiam, C. H., Yeo, K. P., Bisoendial, R., Hii, C. S., McGrath, K. C. Y., Tan, K. W., Heather, A., Alexander, J. S. J., & Angeli, V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.002 · Cited by 309
The Lymphatic System in Health and Disease
Cueni, L. N., & Detmar, M. (2008) · Lymphatic Research and Biology · doi:10.1089/lrb.2008.1008 · Cited by 288
Leukotriene B 4 antagonism ameliorates experimental lymphedema
Tian, W., Rockson, S. G., Jiang, X., Kim, J., Begaye, A., Shuffle, E. M., Tu, A. B., Cribb, M., Nepiyushchikh, Z., Feroze, A. H., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3920 · Cited by 173
Self-citationNakamura, K., Radhakrishnan, K., Wong, Y. M., & Rockson, S. G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008380 · Cited by 118
“Exogenous administration of VEGF-C lessens the severity and slows the progression of experimental lymphedema, including the murine tail model we used [3–4,16].”
BackgroundMethodSelf-citationLohela, M., Heloterä, H., Haiko, P., Dumont, D. J., & Alitalo, K. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.080378 · Cited by 73
Metadata
- Authors
- Szuba, A., Skobe, M., Karkkainen, M. J., Shin, W. S., Beynet, D. P., Rockson, N. B., Dakhil, N., Spilman, S., Goris, M. L., Strauss, H. W., Quertermous, T., Alitalo, K., & Rockson, S. G.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2002-10-18
- Volume
- 16
- Issue
- 14
- Pages
- 1985-1987
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2137100240
- Cited by
- 260
- References
- 37
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.